The phase III MRC COIN trial showed no statistically significant benefit from adding the EGFR-target cetuximab to oxaliplatin-based chemotherapy in first-line treatment of advanced colorectal cancer. This study exploits additional information on HER2-HER3 dimerization to achieve patient stratification and reveal previously hidden subgroups of patients who had differing disease progression and treatment response.

中文翻译：

---

通过 FRET-FLIM 进行 HER2-HER3 异二聚体定量以及 COIN 结直肠试验的患者亚类分析。


III 期 MRC COIN 试验显示，在晚期结直肠癌的一线治疗中，将 EGFR 靶点西妥昔单抗添加到基于奥沙利铂的化疗中，没有统计学上显着的益处。这项研究利用有关 HER2-HER3 二聚化的额外信息来实现患者分层，并揭示以前隐藏的具有不同疾病进展和治疗反应的患者亚组。